Crohn's Pipeline: Janssen Seeks New Niche For Stelara As Biologics Use Rises
This article was originally published in Scrip
Executive Summary
Doctors who treat Crohn's disease are prescribing biologics more frequently than in the past to quickly reduce inflammation, but they're searching for alternatives to tumor necrosis factor (TNF) inhibitors to cut the side effect risks, and that is where the Johnson & Johnson subsidiary Janssen Biotech Inc. may find its best niche for Stelara (ustekinumab).